-
Mashup Score: 2
The FDA approved inhaled treprostinil for the treatment of patients with pulmonary hypertension associated with interstitial lung disease, according to a press release from United Therapeutics.This approval was based on data from the INCREASE study, a phase 3, multicenter, randomized, double-blind, placebo-controlled study that enrolled 326 patients with WHO group 3 pulmonary hypertension
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
#FDA approves inhaled #treprostinil to treat patients with #pulmonaryhypertension associated with #ILD @CardiologyToday https://t.co/9VDQFESHpO
-
-
Mashup Score: 0
Patients receiving the drug experienced improvement in the 6-minute walk test and demonstrated a lower risk of clinical worsening.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
New data supports the efficacy and safety of #treprostinil in patients with pulmonary #hypertension due to interstitial lung disease. https://t.co/quawgzfB6f
-
-
Mashup Score: 0
Patients receiving the drug experienced improvement in the 6-minute walk test and demonstrated a lower risk of clinical worsening.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
The size of the favorable treatment effect on the 6-minute walk distance with inhaled #treprostinil is similar to estimates of the minimum clinically important difference for this test in patients with #pulmonary disease." https://t.co/quawgyXZHF
-
-
Mashup Score: 0
Patients receiving the drug experienced improvement in the 6-minute walk test and demonstrated a lower risk of clinical worsening.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
#Treprostinil improved exercise capacity in patients with pulmonary #hypertension caused by interstitial lung disease, a new study finds. https://t.co/quawgzfB6f
-
-
Mashup Score: 1Inhaled Treprostinil Improves Exercise Capacity in ILD-Related Pulmonary Hypertension - Pulmonology Advisor - 3 year(s) ago
Investigators used changes in peak 6-minute walk distance to compare patients who received treprostinil with patients who received placebo.
Source: Pulmonology AdvisorCategories: Latest Headlines, PulmonologyTweet-
Patients with #PH caused by #ILD experienced greater improvements in exercise capacity with inhaled #treprostinil compared with placebo. Read More: https://t.co/dbmBH0qqn6
-
-
Mashup Score: 0Implantable Infusion Pump for Treprostinil in Pulmonary Arterial Hypertension Is Safe, Feasible - Pulmonology Advisor - 3 year(s) ago
Researchers retrospectively analyzed outcome data from patients with PAH who received an implantable infusion pump to deliver intravenous treprostinil.
Source: Pulmonology AdvisorCategories: Latest Headlines, PulmonologyTweet-
Patients with #PAH who were treated with #treprostinil using an #implantableinfusionpump experienced few serious complications. Read More: https://t.co/LlG8UJ6Mer
-
-
Mashup Score: 1Hospitalizations Lower in Pulmonary Arterial Hypertension Patients Receiving Selexipag or Treprostinil - Pulmonology Advisor - 3 year(s) ago
Real-world hospitalization rates in patients taking selexipag or treprostinil for PAH showed that selexipag is directly associated with lower hospitalization rates.
Source: Pulmonology AdvisorCategories: Latest Headlines, PulmonologyTweet-
Real-world #hospitalization rates in patients taking #selexipag or #treprostinil for #PAH showed that selexipag is associated with lower hospitalization rates. Read More: https://t.co/TcsVYVTa6C
-
-
Mashup Score: 0
Treprostinil (TRE) is a potent pulmonary vasodilator with effects on other pathological aspects of pulmonary arterial hypertension. In this study, the…
Source: bit.lyCategories: Endocrinology, Latest HeadlinesTweet-
'#Prostanoid receptor subtypes involved in #treprostinil-mediated vasodilation of rat pulmonary arteries and in treprostinil-mediated inhibition of collagen gene expression of human lung fibroblasts' Read #openaccess article https://t.co/pO84gwMe2O https://t.co/QEL4i3Egtc
-
-
Mashup Score: 3Inhaled Dry-Powder Form of Treprostinil Improves QoL in Pulmonary Arterial Hypertension - Pulmonology Advisor - 4 year(s) ago
An inhaled dry-powder form of treprostinil was associated with quality of life improvements in patients with pulmonary arterial hypertension.
Source: Pulmonology AdvisorCategories: Latest Headlines, PulmonologyTweet-
An inhaled dry-powder form of #treprostinil was associated with quality of life improvements in patients with #PAH. #Pulmonology Read More: https://t.co/1VPKMrlkYa
-
-
Mashup Score: 0
Inhaled treprostinil was well tolerated and significantly improved exercise capacity and other clinical outcomes over 16 weeks in patients with pulmonary hypertension associated with interstitial lung disease, according to results of the INCREASE study.“INCREASE is the largest and most comprehensive study of this patient group to date,” Steven D. Nathan, MD, director of the Advanced
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
Inhaled #treprostinil improves outcomes in patients with #pulmonaryhypertension associated with interstitial lung disease https://t.co/uLqWXCwWeN
-
#FDA approves inhaled #treprostinil to treat patients with #pulmonaryhypertension associated with #ILD @CardiologyToday https://t.co/O3LJLguaJJ